Strand Therapeutics
Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors and autoimmune disease via its Signal Stack platform, serving biopharma partners through co-development and licensing deals.
- Company typePrivate
- Founded2017
- HeadquartersBoston, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Strand Therapeutics does
Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancer and autoimmune disease, founded in 2017 by MIT synthetic biologists and headquartered in Boston, Massachusetts. Its core offering is the Strand Signal Stack, an integrated platform that combines three proprietary modules: SignalPath lipid nanoparticles for targeted delivery beyond the liver, SignalLock RNA for microRNA-sensing tissue-selective expression, and SignalScript self-replicating and circular RNA for potency and durability. AI/ML-driven design and a proprietary microRNA database spanning hundreds of tissues feed the platform, which is anchored by an exclusive license to foundational synthetic biology IP from MIT's Synthetic Biology Center.
Strand's pipeline comprises three named drug candidates: STX-001, a self-replicating mRNA expressing IL-12 via intratumoral injection, which received FDA IND clearance in January 2024, dosed its first patient in May 2024, and reported complete patient responses in initial Phase 1 data at ASCO 2025; STX-003, a systemically delivered, SignalLock-encrypted IL-12 mRNA for NSCLC and solid tumors expected to enter the clinic in 2026; and STX-005, a circular mRNA construct for in vivo CAR-T in autoimmune disease and hematological malignancies. Strategic pharma investors including Eli Lilly, Regeneron, and Amgen have participated across funding rounds alongside BeiGene, which signed a co-development agreement for solid tumor immuno-oncology in 2021.
The business model is enterprise B2B platform licensing and co-development rather than direct product commercialization, with the company leveraging major industry conferences (J.P. Morgan Healthcare Conference, ASGCT, ASCO, AACR, SITC), peer-reviewed publications in Nature-family journals, and a [email protected] business development channel to drive biopharma partnerships. Strand has raised approximately $153M in Series B (August 2025), $97M in total Series A funding (2021-2022), and multiple NIH SBIR grants, with 101-250 employees and no commercial product revenue at present.
Strand Therapeutics firmographics
Firmographics- Name
- Strand Therapeutics
- Legal name
- Strand Therapeutics Inc.
- Website
- https://strandtx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors and autoimmune disease via its Signal Stack platform, serving biopharma partners through co-development and licensing deals.
- Ownership category
- akta.pro rank
Strand Therapeutics industry classification
Industry- Product category
- Programmable mRNA Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industries
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)
Keywords
Where Strand Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Strand Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Strategic Partnerships & Licensing: Strand is a clinical-stage biotechnology company that has not yet commercialized products. The implied revenue model is based on pharmaceutical partnerships and licensing deals, exemplified by the BeiGene agreement to co-develop solid tumor immuno-oncology therapeutics using Strand's multi-functional mRNA technology. Revenue would derive from upfront payments, milestone payments, and royalties on partnered programs.
- Grant & Non-Dilutive Funding: Strand has supplemented equity financing with non-dilutive funding, including Phase I NIH SBIR contracts to develop mRNA-based CAR-T immunotherapy for Non-Hodgkin's Lymphoma (~ $400,000) and additional SBIR grants for melanoma and breast cancer programs.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
Strand Therapeutics product offering
Product offeringCore offering
Strand Therapeutics is a clinical-stage biotechnology company that develops programmable mRNA therapeutics for cancer and autoimmune diseases, anchored by its Strand Signal Stack platform. The platform integrates three proprietary technologies — SignalPath LNPs for tissue-targeted delivery, SignalLock RNA microRNA-sensing encryption for safety, and SignalScript self-replicating/circular RNA for potency and durability — and powers a pipeline of drug candidates including STX-001 (intratumoral IL-12 for solid tumors, in Phase 1), STX-003 (systemic IL-12 for solid tumors, entering clinic 2026), and STX-005 (in vivo CAR-T for autoimmune and hematological malignancies). Strand monetizes through biopharma partnerships and licensing, exemplified by its BeiGene co-development agreement.
Product overview
Strand Therapeutics is a clinical-stage biotechnology company whose offering is structured as a platform-plus-modules architecture built around a single core platform — the Strand Signal Stack — that integrates three named modules (SignalPath LNPs for targeted delivery, SignalLock RNA for tissue-selective safety, and SignalScript RNA for potency and durability). This core platform powers a pipeline of three named therapeutic drug candidates (STX-001, STX-003, and STX-005) targeting cancers and autoimmune diseases, with STX-001 in Phase 1 clinical trials and STX-003 expected to enter the clinic in 2026. Together, the Signal Stack platform modules produce a plug-and-play delivery system that generates Strand's pipeline of self-replicating mRNA and circular RNA therapeutics for solid tumors, hematological malignancies, and autoimmune indications.
Differentiator
Problem solved
Functional benefit
Brands
- Strand Signal Stack: End-to-end mRNA technology platform comprising SignalPath LNPs (targeted delivery), SignalLock RNA (microRNA-sensing selectivity), and SignalScript RNA (potent self-replicating and circular RNA).
- SignalPath LNPs
- SignalLock RNA
- SignalScript RNA
Products and services
- Strand Signal Stack
- STX-001
- STX-003
- STX-005
Quantifiable outcome
- Complete patient responses observed in Phase 1 dose escalation of STX-001 in advanced solid tumors (intratumoral delivery); near-clear scans at week 30 vs metastatic lesions at week 12
- +2 more outcomes
Companies that use Strand Therapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
Strand Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Strand Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered strategic, flagship and minor.
- Jeb Keiper (Independent Board Director)strategicJeb Keiper was appointed to Strand Therapeutics' Board of Directors in December 2025. He previously served as President and CEO of Nimbus Therapeutics (2018-2025), overseeing $650M+ in equity funding and $7B+ in deal value. He also serves on boards of Cardurion Pharmaceuticals and ROME Therapeutics.
- BeiGeneflagshipStrand Therapeutics entered into an agreement with BeiGene to develop solid tumor immuno-oncology therapeutics based on Strand's next-generation, multi-functional mRNA technology. The collaboration leverages Strand's programmable mRNA platform to advance novel immuno-oncology treatments.
- Bristol-Myers Squibb (BMS)minorStrand was a 2018 winner of BMS's 'Golden Ticket' contest, which awarded lab space to innovative local startups as part of BMS's effort to increase visibility in the Cambridge/Boston life science community and support the opening of BMS' Cambridge R&D site.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Strand Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company with LNP and AAV delivery platforms across oncology, rare disease, and autoimmune indications. Comparable as a nucleic acid therapeutic developer with LNP delivery expertise overlapping Strand's SignalPath LNPs, though using gene editing rather than mRNA.
- Translate Bio (Sanofi): mRNA therapeutics developer acquired by Sanofi in 2021, focused on pulmonary and other rare disease indications using lipid nanoparticle delivery. Comparable as a clinical-stage mRNA company with LNP delivery expertise overlapping with Strand's SignalPath LNPs, now operating within Sanofi's broader pipeline.
- Moderna: Largest publicly traded mRNA therapeutics company with broad pipeline across infectious disease, oncology, and rare diseases. Direct comparable because both companies develop mRNA-based therapeutics, though Moderna operates at vastly greater scale and across multiple modalities beyond Strand's programmable mRNA focus.
- BioNTech: Global mRNA leader with oncology, infectious disease, and immuno-oncology programs. Comparable to Strand because both pursue mRNA-based cancer therapeutics, but BioNTech is substantially larger and more diversified, including FixVac and individualized neoantigen approaches.
Others
- Acuitas Therapeutics: Privately held biotechnology company developing lipid nanoparticle delivery systems for nucleic acid therapeutics, including mRNA and gene editing payloads. Comparable as an LNP technology provider and enabler in the same delivery ecosystem that Strand's SignalPath LNPs compete within; serves multiple mRNA developers including partners of Moderna and BioNTech.
Direct peers
- Omega Therapeutics: Clinical-stage programmable mRNA therapeutics company engineering omega epigenetic controllers via mRNA delivery. Direct peer in the programmable mRNA category with similar tissue-selective expression concept via engineered RNA circuits, focused on oncology and rare disease.
- Arcturus Therapeutics: Clinical-stage mRNA therapeutics company developing self-replicating and conventional mRNA platforms with proprietary LNP delivery. Direct comparable because both pursue self-amplifying mRNA for rare diseases and oncology, including STARR mRNA technology overlapping with Strand's SignalScript RNA.
- Orna Therapeutics: Clinical-stage biotechnology company developing circular RNA (oRNA) therapeutics with proprietary LNP delivery for oncology, autoimmune disease, and genetic disorders. Direct peer because Strand's SignalScript RNA and Orna's oRNA both develop circular RNA payloads with overlapping target indications.
Emerging players
- Laronde (now Ascidian Therapeutics): Developer of engineered circular RNA (eRNA) therapeutics founded by Flagship Pioneering. Comparable as an emerging programmable RNA player whose circular RNA modality overlaps with Strand's SignalScript RNA; now operating as Ascidian Therapeutics with a focus on RNA editing for genetic diseases.
- Verve Therapeutics: Clinical-stage in vivo gene editing company using LNP delivery and base editing for cardiovascular disease. Comparable as an LNP-delivered nucleic acid therapeutic developer; both companies rely on lipid nanoparticle delivery beyond the liver, though Strand focuses on mRNA rather than gene editing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Strand Therapeutics social profiles
Digital presenceStrand Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Strand Therapeutics leadership team
Management profileNumber of profiles
Profiles18 records
Strand Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Strand Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Strand Therapeutics
What does Strand Therapeutics do?
Strand Therapeutics is a clinical-stage biotechnology company that develops programmable mRNA therapeutics for cancer and autoimmune diseases, anchored by its Strand Signal Stack platform. The platform integrates three proprietary technologies — SignalPath LNPs for tissue-targeted delivery, SignalLock RNA microRNA-sensing encryption for safety, and SignalScript self-replicating/circular RNA for potency and durability — and powers a pipeline of drug candidates including STX-001 (intratumoral IL-12 for solid tumors, in Phase 1), STX-003 (systemic IL-12 for solid tumors, entering clinic 2026), and STX-005 (in vivo CAR-T for autoimmune and hematological malignancies). Strand monetizes through biopharma partnerships and licensing, exemplified by its BeiGene co-development agreement.
Is Strand Therapeutics a public or private company?
Strand Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Strand Therapeutics founded?
Strand Therapeutics was founded in 2017. It employs 101 to 250 people.
Where is Strand Therapeutics based?
Strand Therapeutics is headquartered in Boston, United States, in the North America region.
How does Strand Therapeutics make money?
Two revenue lines are on record. Strategic Partnerships & Licensing is the primary driver. The others are grant & Non-Dilutive Funding.
Who are Strand Therapeutics's main competitors?
Broad incumbents on record are Intellia Therapeutics, Translate Bio (Sanofi), Moderna and BioNTech. Acuitas Therapeutics is listed as an others. Direct peers are Omega Therapeutics, Arcturus Therapeutics and Orna Therapeutics. Emerging players are Laronde (now Ascidian Therapeutics) and Verve Therapeutics.
Does Strand Therapeutics have an API?
No public API is recorded for Strand Therapeutics.
What industry is Strand Therapeutics in?
Strand Therapeutics's product category is Programmable mRNA Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.